-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RNLXuuYvbm+xkfUUhzJX9xXBW40iq2Zb9UvddShbavb4K5ArF54eH8jrAa4f/TVs P8u3ZL8twCYG5AHQw9h+pg== 0001144204-10-007821.txt : 20100216 0001144204-10-007821.hdr.sgml : 20100215 20100216103202 ACCESSION NUMBER: 0001144204-10-007821 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100216 DATE AS OF CHANGE: 20100216 GROUP MEMBERS: CHRIS JOHNSON GROUP MEMBERS: DAVID GRIN GROUP MEMBERS: EUGENE GRIN GROUP MEMBERS: LAURUS CAPITAL MANAGEMENT, LLC GROUP MEMBERS: PSOURCE STRUCTURED DEBT LIMITED GROUP MEMBERS: RUSSELL SMITH GROUP MEMBERS: VALENS CAPITAL MANAGEMENT, LLC GROUP MEMBERS: VALENS OFFSHORE SPV I, LTD. GROUP MEMBERS: VALENS U.S. SPV I, LLC GROUP MEMBERS: VALENS U.S. SPV II, CORP. FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LAURUS MASTER FUND LTD CENTRAL INDEX KEY: 0001189294 IRS NUMBER: 980337673 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 152 W 57TH ST CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2125415800 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ACCENTIA BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001310094 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81399 FILM NUMBER: 10603134 BUSINESS ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVE STREET 2: SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 BUSINESS PHONE: 8138642562 MAIL ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVE STREET 2: SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 SC 13G/A 1 v173754_sc13ga.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (AMENDMENT NO. 2)* ACCENTIA BIOPHARMACEUTICALS, INC. ----------------------------------- (Name of Issuer) Common Stock, par value $0.001 per share ---------------------------------------- (Title of Class of Securities) 00430L10 --------- (CUSIP Number) December 31, 2009 -------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1 (b) |X| Rule 13d-1 (c) |_| Rule 13d-1 (d) The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Laurus Master Fund, Ltd. (In Liquidation)* S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 98-0337673 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: PSource Structured Debt Limited S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Guernsey - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Laurus Capital Management, LLC S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 13-4150669 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99 % - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Valens Offshore SPV I, Ltd. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Valens U.S. SPV II, Corp. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 26-0811267 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - --------- ---------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Valens U.S. SPV I, LLC S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 20-8903266 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ---- -------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ---- -------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ---- -------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - --------- ---------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - --------- ---------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - --------- ---------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - --------- ---------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Valens Capital Management, LLC S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 20-8903345 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ---- -------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ---- -------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ---- -------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Chris Johnson - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Russell Smith - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: David Grin - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States and Israel - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock. * SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99 % - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Eugene Grin - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER: 0 shares of Common Stock.* SHARES ------------------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER: 6,455,581 shares of Common Stock. * OWNED BY ------------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER: 0 shares of Common Stock. * REPORTING ------------------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER: 6,455,581 shares of Common Stock. * - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,455,581 shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.99 % - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 Item 1(a). Name of Issuer: Accentia Biopharmaceuticals, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 324 SOUTH HYDE PARK AVE SUITE 350 TAMPA FL 33606 Item 2(a). Name of Person Filing: Laurus Master Fund, Ltd. (In Liquidation)* This Schedule 13G, as amended, is also filed on behalf of PSource Structured Debt Limited, a closed ended company incorporated with limited liability in Guernsey, Laurus Capital Management, LLC, a Delaware limited liability company, Valens Offshore SPV I, Ltd., a Cayman Islands limited company, Valens Offshore SPV II, Corp., a Delaware corporation, Valens U.S. SPV I, LLC, a Delaware limited liability company, Valens Capital Management, LLC, a Delaware limited liability company, Chris Johnson, Russell Smith, Eugene Grin and David Grin. Laurus Master Fund, Ltd. (In Liquidation) is in official liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The Joint Official Liquidators have discretion over the management of Laurus Master Fund, Ltd. (In Liquidation) and the disposition of its assets, including the securities owned by Laurus Master Fund, Ltd. (In Liquidation) reported in this Schedule 13G, as amended. Laurus Capital Management, LLC, acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to Laurus Master Fund, Ltd. (In Liquidation) and its two feeder funds concerning their respective assets, including the securities owned by Laurus Master Fund, Ltd. (In Liquidation) reported in this Schedule 13G, as amended, subject to the oversight and preapproval rights of the Joint Official Liquidators and Laurus Capital Management, LLC's obligations to Laurus Master Fund, Ltd. (In Liquidation) under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the Joint Official Liquidators at their discretion. Laurus Capital Management, LLC manages PSource Structured Debt Limited, subject to certain preapproval rights of the board of directors of PSource Structured Debt Limited. Valens Capital Management, LLC manages Valens Offshore SPV I Ltd., Valens Offshore SPV II, Corp., and Valens U.S. SPV I, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by Laurus Master Fund, Ltd. (In Liquidation) (subject to the oversight and preapproval rights of the Joint Official Liquidators), PSource Structured Debt Limited, Valens Offshore SPV I, Ltd., Valens Offshore SPV II, Corp., and Valens U.S. SPV I, LLC reported in this Schedule 13G, as amended. The Joint Official Liquidators share voting and investment power over the securities owned by Laurus Master Fund, Ltd. (In Liquidation). Information related to each of Laurus Capital Management, LLC, Valens Offshore SPV I Ltd., Valens Offshore SPV II, Corp., PSource Structured Debt Limited, Valens U.S. SPV I, LLC, Valens Capital Management, LLC, Chris Johnson, Russell Smith, Eugene Grin and David Grin is set forth on Appendix A hereto. Item 2(b). Address of Principal Business Office or if none, Residence: c/o Laurus Capital Management, LLC, 335 Madison Avenue, 10th Floor, New York, NY 10017 Item 2(c). Citizenship: Cayman Islands Item 2(d). Title of Class of Securities: Common Stock ("Common Stock") Item 2(e). CUSIP Number: 00430L10 Item 3. Not Applicable Item 4. Ownership: (a) Amount Beneficially Owned: 6,455,581 shares of Common Stock (b) Percent of Class: 9.99% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 shares of Common Stock.* (ii) shared power to vote or to direct the vote: 6,455,581 shares of Common Stock. * (iii) sole power to dispose or to direct the disposition of: 0 shares of Common Stock. * (iv) shared power to dispose or to direct the disposition of: 6,455,581 shares of Common Stock. * Item 5. Ownership of Five Percent or Less of a Class: Not applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not applicable Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not applicable Item 8. Identification and Classification of Members of the Group: Not applicable Item 9. Notice of Dissolution of Group: Not applicable Item 10. Certification: By signing below, I certify to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. - ----------------------------------- *Based on 58,243,115 shares of the common stock, par value $0.001 per share (the "Shares") issued and outstanding of Accentia Biopharmaceuticals, Inc., a Florida corporation (the "Company") as of December 31, 2009, as reported by the Company to the Investors on February 11, 2010. As of December 31, 2009, Laurus Master Fund. Ltd. (In Liquidation) (the "Fund"), PSource Structured Debt Limited ("PSource"), Valens U.S. SPV I, LLC ("Valens US"), Valens Offshore SPV I, Ltd. ("VOFF SPV I"), and Valens Offshore SPV II, Corp. ("VOFF SPV II", and together with the Fund, PSource, Valens US, and VOFF SPV I, the "Investors") collectively held (i) 78,255 Shares, (ii) a warrant (the "ABPIAR1B Warrant") to acquire 4,024,398 Shares at an exercise price of $2.67 per share, subject to certain adjustments, (iii) a warrant (the "ABBPIAR1A Warrant") to acquire 1,000,000 warrants at an exercise price of $2.67 per share, subject to certain adjustments, (iv) a warrant (the "ABPIPRELONG Warrant") to acquire 561,798 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (v) a warrant (the "ABPIPRESHRT Warrant") to acquire 1,123,596 Shares at an exercise price of $2.67 per Share, subject to certain adjustments, (vi) series A-1 convertible preferred stock (the "ABPIPREF1") in the outstanding stated value of $2,624,996 convertible into Shares at a conversion price of $2.67 per Share, subject to certain adjustments, and (vii) a secured convertible note (the "Note") in the outstanding principal amount of $3,315,782 convertible into Shares at an exercise price of $1.20 per Share, subject to certain adjustments. The Note, the ABPIPREF1 and the Warrants each contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 4.99% or 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation in the Note, the ABPIPREF1 and the Warrants may be waived by the Investors upon at least either 61 days or 75 days prior notice (as set forth and pursuant to the terms of the applicable instrument) to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument). The Fund is in liquidation under the supervision of the Grand Court of the Cayman Islands. The Joint Official Liquidators ("JOLs") are Chris Johnson and Russell Smith of Johnson Smith Associates, Ltd. The JOLs have discretion over the management of the Fund and the disposition of its assets, including the securities owned by the Fund reported in this Schedule 13G, as amended. Laurus Capital Management, LLC ("LCM") acting through its controlling principals, Eugene Grin and David Grin, provides day to day investment management services to the Fund and its two feeder funds concerning their respective assets, including the securities owned by the Fund reported in this Schedule 13G, as amended, subject to certain oversight and preapproval rights of the JOLs and LCM's obligations to the Fund under the Seventh Amended and Restated Investment Management Agreement of April 26, 2007, as amended, restated, modified and/or supplemented from time to time; all of the foregoing subject to specific directions otherwise given by the JOLs at their discretion. PSource is managed by LCM, subject to certain preapproval rights of the board of directors of Psource. Valens US, VOFF SPV I and VOFF SPV II are managed by Valens Capital Management, LLC ("VCM"). Eugene Grin and David Grin, through other entities, are the controlling principals of LCM and VCM and share voting and investment power over the securities owned by the Fund (subject to the oversight and preapproval rights of the JOLs), PSource, Valens US, VOFF SPV I and VOFF SPV II reported in this Schedule 13G, as amended. The JOLs share voting and investment power over the securities owned by the Fund. CUSIP No. 00430L10 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 12, 2010 ---------------- Date Laurus Master Fund, Ltd. (In Liquidation) /s/ Russell Smith ----------------------------------------- Russell Smith Joint Official Liquidator (for the account of Laurus Master Fund, Ltd. and with no personal liability) February 12, 2010 CUSIP No. 00430L10 APPENDIX A A. Name: Laurus Capital Management, LLC, a Delaware limited liability company Business 335 Madison Avenue, 10th Floor Address: New York, New York 10017 Place of Organization: Delaware B. Name: PSource Structured Debt Limited, a closed-ended company incorporated with limited liability in Guernsey Business c/o Laurus Capital Management, LLC Address: 335 Madison Avenue, 10th Floor New York, New York 10017 Place of Organization: Guernsey C. Name: Valens Offshore SPV I, Ltd., a Cayman Islands limited company Business c/o Valens Capital Management, LLC Address: 335 Madison Avenue, 10th Floor New York, New York 10017 Place of Organization: Cayman Islands D. Name: Valens Offshore SPV II, Corp., a Delaware corporation Business c/o Valens Capital Management, LLC Address: 335 Madison Avenue, 10th Floor New York, New York 10017 Place of Organization: Delaware E. Name: Valens U.S. SPV I, LLC, a Delaware limited liability company Business 335 Madison Avenue, 10th Floor Address: New York, New York 10017 Place of Organization: Delaware F. Name: Valens Capital Management, LLC, a Delaware limited liability company Business 335 Madison Avenue, 10th Floor Address New York, New York 10017 Place of Organization: Delaware G. Name: David Grin Business 335 Madison Avenue, 10th Floor Address: New York, New York 10017 Principal Principal of Valens Capital Management, LLC Occupation: Principal of Laurus Capital Management, LLC Citizenship: United States and Israel H. Name: Eugene Grin Business 335 Madison Avenue, 10th Floor Address: New York, New York 10017 Principal Principal of Valens Capital Management, LLC Occupation: Principal of Laurus Capital Management, LLC Citizenship: United States I. Name: Chris Johnson Business Address: Elizabethan Square, 80 Shedden Road, George Town, Grand Cayman, Cayman Islands KY1-1104 Principal Occupation: Managing Director, Johnson Smith Associates Ltd. Citizenship: Cayman Islands J. Name: Russell Smith Business Address: Elizabethan Square, 80 Shedden Road, George Town, Grand Cayman, Cayman Islands KY1-1104 Principal Occupation: Director, Johnson Smith Associates Ltd. Citizenship: Cayman Islands CUSIP No. 00430L10 Each of Laurus Capital Management, LLC, PSource Structured Debt Limited, Valens Offshore SPV I, Ltd., Valens Offshore SPV II, Corp., Valens U.S. SPV I, LLC, Valens Capital Management, LLC, Chris Johnson, Russell Smith, David Grin and Eugene Grin hereby agree, by their execution below, that the Schedule 13G to which this Appendix A is attached is filed on behalf of each of them, respectively. PSource Structured Debt Limited Laurus Capital Management, LLC, By Laurus Capital Management, LLC, individually and as investment manager /s/ Eugene Grin - ----------------------------------------- Eugene Grin Authorized Signatory February 12, 2010 Valens U.S. SPV I, LLC Valens Offshore SPV I, Ltd. Valens Offshore SPV II, Corp. Valens Capital Management, LLC By Valens Capital Management, LLC individually and as investment manager /s/ Eugene Grin - ----------------------------------------- Eugene Grin Authorized Signatory February 12, 2010 /s/ Chris Johnson - ----------------------------------------- Chris Johnson, on his individual behalf February 12, 2010 /s/ Russell Smith - ----------------------------------------- Russell Smith, on his individual behalf February 12, 2010 /s/ David Grin - ----------------------------------------- David Grin, individually on his own behalf February 12, 2010 /s/ Eugene Grin - ----------------------------------------- Eugene Grin, individually on his own behalf February 12, 2010 -----END PRIVACY-ENHANCED MESSAGE-----